Data / Form D filings / Synedgen, Inc.
Synedgen, Inc.: Form D filings
Synedgen, Inc., a pharmaceuticals company in Claremont, CA, filed 15 Form D notices with the SEC between 2009 and 2024. The latest, on October 1, 2024, reports $1.8 million sold of a $2 million offering to 4 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1420 N. CLAREMONT BOULEVARD, SUITE 105D, Claremont, CA, 91711
- Phone
- (909) 447-6858
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1471618
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 1, 2024 | New notice | $2,000,000 | $1,750,000 | $250,000 | 4 | Sep 11, 2024 | sec.gov |
| Jul 12, 2019 | New notice | $3,000,000 | $2,500,000 | $500,000 | 1 | Jun 30, 2019 | sec.gov |
| Sep 12, 2017 | New notice | $3,000,000 | $3,000,000 | 3 | Aug 30, 2017 | sec.gov | |
| Nov 8, 2016 | New notice | $3,500,000 | $3,000,000 | $500,000 | 1 | Oct 28, 2016 | sec.gov |
| Apr 27, 2016 | New notice | $6,500,000 | $6,000,000 | $500,000 | 1 | Apr 13, 2016 | sec.gov |
| Mar 3, 2015 | New notice | $4,000,000 | $3,500,000 | $500,000 | 1 | Feb 24, 2015 | sec.gov |
| Aug 13, 2014 | New notice | $607,440 | $607,440 | 15 | Aug 7, 2014 | sec.gov | |
| Jul 12, 2013 | Amendment | $4,000,000 | $3,978,957 | $21,043 | 38 | Oct 10, 2009 | sec.gov |
| Apr 29, 2013 | Amendment | $4,000,000 | $3,183,437 | $816,563 | 26 | Oct 10, 2009 | sec.gov |
| May 14, 2012 | Amendment | $4,000,000 | $2,454,271 | $1,545,729 | 15 | Oct 10, 2009 | sec.gov |
| May 14, 2012 | Amendment | $4,000,000 | $2,454,271 | $1,545,729 | 15 | Oct 10, 2009 | sec.gov |
| May 14, 2012 | Amendment | $4,000,000 | $2,454,271 | $1,545,729 | 15 | Oct 10, 2009 | sec.gov |
| May 14, 2012 | Amendment | $4,000,000 | $2,454,271 | $1,545,729 | 15 | Oct 10, 2009 | sec.gov |
| Sep 14, 2011 | Amendment | $4,000,000 | $2,107,006 | $1,892,994 | 14 | Oct 10, 2009 | sec.gov |
| Oct 20, 2009 | New notice | $4,000,000 | $995,005 | $3,004,995 | 10 | Oct 10, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Shenda Baker | Executive Officer, Director | |
| William P. Wiesmann | Executive Officer, Director | |
| Paul C. Grint | Director | |
| Hal W. Oien | Director | |
| Andrew W. Miller | Director | |
| Daniel C. Bradbury | Director | |
| Kaveri P. Parker | Executive Officer | |
| Kenton P. Gregory | Director |
Other pharmaceuticals companies in California that filed recently
- Anvion Bio, Inc. $100,000 · Oct 7, 2026
- Aqur Biosciences, Inc. $1.5 million · Sep 18, 2026
- BTB Therapeutics, Inc. $8.9 million · Aug 12, 2026
Every Form D from the week of Sep 30, 2024 · All recent filings in California · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Synedgen, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.